Key Takeaways
- Profit compounding outruns revenue: PAT grew 20% against 13% revenue growth, net worth expanded 26% YoY, and cash conversion hit 80% of PAT, all while two backward-integration units are still loss-making.
- US business reaches escape velocity: The US unit, once cash-burning, delivered INR 470 cr EBITDA and own-label revenue nearly touched INR 100 cr in its first full year, with weekly ordering now routine from the four largest wholesalers.
- Receivables spike is explainable, not alarming: 136 days includes 11 days of non-cash FCTR and a large El Salvador tender shipped in Feb/March; collection is due by end of Q2 and the company has virtually zero bad-debt history.
- Capacity is the binding constraint: Plants are running at optimum, 40–50% of LATAM business is outsourced, and the order book is full for six months; management is turning away lower-margin volume.
- What to watch next quarter: Whether the El Salvador tender receivable actually converts by end-Q2, the pace of own-label launches from the 15 acquired ANDAs, and any closure on the active ANDA acquisition flagged as imminent.
US Business: From Cash Burn to Compounder
- EBITDA transformation: CSL delivered INR 142 cr EBITDA at 30% margin in FY26, up from INR 102 cr (27.9%) last year; Q4 exit margin was 33%.
- Own-label traction: Nearly INR 100 cr revenue in the first full year with no cannibalization of the B2B base; target is to double this to INR 200 cr next year.
- Portfolio depth building: 10 ANDAs approved in the last four quarters, 15 acquired ANDAs now launching, and another ANDA acquisition expected to close in coming weeks; total tally stands at 60 ANDAs.
- Revenue composition: More than 90% of US revenue still came from older, already-marketed products, meaning the approved and acquired ANDAs are largely incremental revenue yet to flow through.
Vivek Partheeban: "We are not seeing a dearth of orders. In fact, we have an order book that is full for another six months almost."
LATAM: Tender Lumpiness and Structural Build-Out
- Quarterly spike explained: LATAM revenue jumped from INR 432 cr to INR 470 cr on a single El Salvador tender worth ~INR 1.6 cr; supplies shipped in Feb/March, receivable collection due by end of Q2.
- Currency tailwind embedded: El Salvador uses the USD, so the delay in collection actually increases profit as the rupee weakens; there is no bottom-line impact from the extended receivable.
- Mexico entry underway: Land purchased, facility plans being drawn up, construction to start by Q3 or Q4; management targets ~$4 mn in sales from Mexico over the coming two quarters.
- Chile ramp beginning: Business starts this year; 135 products worth ~$10 mn to be supplied over the next 18 months, with bio-studies underway for 40+ products in a high-margin, low-competition market.
- Distribution depth: Two solid distribution candidates identified in Chile with own sales and logistics teams; company is also trying to buy a distribution company in Chile, Mexico, or Brazil.
- Brand marketing launch: Central nervous system line with bio-equivalence for 12+ products launching in Dominican Republic, Guatemala, and Nicaragua in September.
- Pharmacy shelf-space moat: Independent pharmacies, supported by Caplin through COVID, now give the company 41% shelf space, creating a structural advantage in Central America.
C.C. Paarthipan: "When you develop the credence for your business over a period of time and you establish the KPIs through video SOPs, then it is simply going above and beyond. That is the deliberate growth."
Capacity Expansion: The Unlocking Catalyst
- Current constraint: Facilities are running at optimum; 40–50% of LATAM business is outsourced because finding good outsourcing facilities is difficult, directly limiting top-line growth.
- Injectable lines multiplying: From one USFDA factory with five lines today to 17 injectable lines for the US and other regulated markets over the next two to three years.
- Phase III and oncology: Phase III construction is at an advanced stage; the oncology injection plant was capitalized in April after MOH approvals.
- IV bag capacity tripling: Expansion underway within Phase I and II to 3x existing IV bag line capacity.
- New modalities: Pondicherry facility for larger-capacity oral solids and derma being constructed; oncology API plant being completed; liquid manufacturing facility planned for Central America.
- Capex runway: INR 510 cr residual to be spent over the next 18–24 months, funded entirely from internal cash generation; this excludes Mexico, Chile, warehouses, quality control labs, or any inorganic move.
Balance Sheet & Cash Flow Quality
- Net worth compounding: Net worth expanded by INR 745 cr, a 26% increase in one year, signaling intrinsic value creation beyond the P&L.
- Forex translation reserve: FCTR movement of INR 141 cr went directly into reserves; as a 100% export-oriented company, forex assets (INR 177 cr) far outweigh liabilities (INR 22.2 cr).
- Cash conversion: CFO at INR 523 cr, representing 80% of PAT, confirming profits are real cash.
- Inventory as latent revenue: The model of holding minimum six months of stock in subsidiary warehouses means inventory held in-market and WIP has the potential to raise ~INR 900 cr in sales.
- Receivables comfort: Management is comfortable with 100–120 days, possibly up to 130 days going forward; the company has virtually zero bad-debt history, with higher receivables mostly from government entities.
- Reserves trajectory: Reserves and surplus likely to continue rising despite the capex cycle over the next 18–24 months.
C.C. Paarthipan: "During volatile periods, the cash becomes the strategic oxygen."
Margin Structure & Drags
- Drags are visible and temporary: The API unit and Amaris Clinical (backward integration) are not yet breaking even; despite these, PAT margin holds at 27–28% and EBITDA at 38–39%.
- Input cost pass-through: COGS impact from glass and plastics price increases is less than 1.5–2% for the highest-impact product; the subsidiary-warehouse model lets the company design selling prices accordingly, so raw material volatility does not translate into major margin pressure.
- Currency stability in core markets: Guatemala is stable; Nicaragua and Honduras see only 3–4% fluctuation; El Salvador, Panama, and Ecuador use the dollar; Costa Rica and Chile have been stable for 4–5 years.
- 18–24 month margin view: Numbers expected to return to previous levels in LATAM after 18 months; beyond that, margins are likely to be maintained at the same level or potentially inch up.
Vivek Partheeban: "Despite all these drags on our bottom line, we are still looking at 27%, 28% PAT and 38%, 39% EBITDA, which in my opinion, at least from whatever I have seen in our size segment, nobody else has these numbers."
Inorganic & Strategic Optionality
- Acquisition philosophy: Management will not acquire for the sake of it; only a meaningful acquisition is worth pursuing, and the company has enough cash resources to act when the right target appears.
- Target types: A meaningful facility acquisition, ANDA portfolios, or distribution entities in the US or in countries where Caplin is early or new.
- Active pipeline: One ANDA acquisition expected to close in coming weeks; distribution company targets being evaluated in Chile, Mexico, and Brazil.
- Non-US regulated markets: 54 products filed globally in Canada, Europe, Australia, and South Africa; meaningful revenue from these markets expected in the coming few years.
C.C. Paarthipan: "Going for the sake of acquisition, I would not advise us to go for actually acquisition without going for a meaningful acquisition. That will be a vanity."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US own-label revenue | Double from ~INR 100 cr to ~INR 200 cr | Next year (FY27) |
| Overall growth expectation | 25% to 30% | Next year (FY27) |
| El Salvador tender receivable collection | Full collection of amount shipped in Feb/March | End of Q2 FY27 |
| Mexico facility construction start | Building to begin | Q3 or Q4 FY27 |
| Mexico sales target | ~$4 mn | Coming two quarters |
| Chile product supply | 135 products worth ~$10 mn | Next 18 months |
| Residual capex spend | INR 510 cr | Next 18–24 months |
| Injectable line count | 17 lines for US and regulated markets | Next 2–3 years |
| LATAM numbers recovery | Return to previous growth levels | 18 months and beyond |
| Receivable days range | Comfortable at 100–120 days, possibly up to 130 days | Going forward |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue (FY26) | ₹2,300 cr, doubled from ₹1,085 cr in FY25-26 |
| Revenue growth (FY26) | 13%, profit growth of 20% ahead of revenue growth |
| EBITDA, PBT, PAT growth (FY26) | 2.5x increase over the last five years |
| Net worth | ₹3,331 cr, expanded by ₹745 cr during the year, 26% growth |
| Cash reserves | ₹1,471 cr, free cash reserves tripled from ₹470 cr |
| Liquid assets | ₹2,726 cr, tripled from ₹928 cr |
| Operating cash flow (FY26) | ₹523 cr, representing 80% cash conversion of PAT |
| R&D spend (FY26) | ~₹100 cr, crossed ₹100 cr for the first time, almost 5% of turnover |
| Capex incurred (FY26) | ₹248 cr, peak rate for the year |
| Receivable days | 136 days, 11 days attributable to FCTR; would have been 125 days otherwise |
| US business revenue growth | ~20% |
| Caplin Steriles EBITDA margin (Q4) | 33% |
| Caplin Steriles EBITDA margin (FY26) | 30%, up from 27.9% in FY25 |
| US own-label revenue (FY26) | ~₹100 cr, in first full year of operations |
| US ANDA tally | 60 ANDAs as of May 2026, 10 approvals and 15 acquisitions in FY26 |
| LATAM ex-US revenue (Q4) | ₹470 cr, up from ₹432 cr in Q3, driven by El Salvador tender |
| Mexico expected sales (next two quarters) | ~$4 million |
| Chile product registrations | 135 registrations received, ~40 more submitted |
| Central America pharmacy shelf space | 41%, expected to reach 57% with liquid registrations |
| Forex translation reserve movement | ₹141 cr, added directly to reserves |
| Fixed assets turnover ratio | 3.91x |
| Inventory sales potential (market and WIP) | ~₹900 cr |
| Residual capex to be spent | ₹510 cr, over next 18–24 months |